BioCryst to Announce First Quarter 2017 Financial Results May 4
April 24 2017 - 12:01PM
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today
announced that its first quarter 2017 financial results will be
reported on Thursday, May 4th, 2017.
BioCryst will host a conference call and webcast
at 11:00 a.m. Eastern Time to discuss financial results and to
provide an update regarding the Company’s clinical development
programs. The call will be led by Jon P. Stonehouse,
President & Chief Executive Officer, Thomas R. Staab II, Senior
Vice President & Chief Financial Officer, and Dr. Bill
Sheridan, Senior Vice President and Chief Medical Officer.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and
develops novel small molecule drugs that block key enzymes involved
in rare diseases. BioCryst currently has several ongoing
development programs: BCX7353 and second generation oral inhibitors
of plasma kallikrein for hereditary angioedema, and galidesivir, a
broad spectrum viral RNA polymerase inhibitor that is a potential
treatment for filoviruses. RAPIVAB® (peramivir injection), a viral
neuraminidase inhibitor for the treatment of influenza, is
BioCryst’s first approved product and is currently marketed in the
U.S., Japan, Taiwan and Korea. Post-marketing commitment
development activities are ongoing, as well as activities to
support regulatory approvals in other territories. For more
information, please visit the Company's website at
www.BioCryst.com.
This press release contains forward-looking
statements, including statements regarding future results and
achievements. These statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performances or achievements expressed or implied
by the forward-looking statements. Please refer to the documents
BioCryst files periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024